Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab in IV Steroid-Refractory Ulcerative Colitis
NCT00279422Phase 3Terminated
- Sponsor
- Facet Biotech Corporation
- Start
- Feb 2006
- Primary completion
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Visilizumab with Placebo (2 arms). Primary endpoint: Induction of clinical response at 45 days. Started Feb 2006; status: terminated.
02
Drugs
visilizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00279422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00279422.